IL-6 also promotes Th17 differentiation and inhibits Treg differentiation, suggesting targeting IL-6/IL-6R may have clinical applications in treating autoimmune disease and organ rejection [127,129]. This evidence concerns the gene IL6R and autoimmune disease.